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Drug targetWe investigated the behavior of renal cells cultivated in microﬂuidic biochips when exposed to 50 μM of
ifosfamide, an antineoplastic drug treatment. The microarray analysis revealed that ifosfamide had any effect
in Petri conditions. The microﬂuidic biochips induced an early inﬂammatory response in the MDCK in the
untreated cells. This was attributed to cells adapting to the dynamics and micro environment created by
the biochips. This led to modulations in the mitochondria dysfunction pathway, the Nrf-2 and oxidative stress
pathways and some related cancer genes. When exposed to 50 μM of ifosfamide, we detected a modulation of
the pathways related to the cancer and inﬂammation in the MDCK cultivated in the biochips via modulation
of the ATM, p53, MAP Kinase, Nrf-2 and NFKB signaling. In addition, the genes identiﬁed and related proteins
affected by the ifosfamide treatment in the biochips such as TXNRD1, HSP40 (DNAJB4 and DNAJB9), HSP70
(HSPA9), p21 (CDKN1A), TP53, IKBalpha (NFKBIA) are reported to be the molecular targets in cancer therapy.
We also found that the integrin pathway was perturbed with the ifosfamide treatment. Finally, the MYC proto-
oncogene appeared to be a potential bridge between the integrin signaling and the anti-inﬂammatory response.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Research in drug development covers a wide range of steps before
being able to discover an active new compound for commercializa-
tion. In this context, the purpose of alternative in vitro methods is to
evaluate the pharmacological potential of a candidate compound be-
fore initiating animal tests. The experiments conducted during this
stage must assess the drug's metabolism, its metabolic stability, the
opportunities for competition and inhibition between various drugs,
and its cytotoxicity [1–4]. To do so, a wide range of in vitromodels are
developed in order to be able to reproduce in vivo physiological situa-
tions. In this context, several research teams have proposed a new ap-
proach for reproducing certain physiological conditions based on the
development of microscale bio-artiﬁcial organs such as the liver or kid-
neys. The tissues of interest are cultivated in microﬂuidic biochips
inwhich themicro environment plays a part in enhancing cellular func-
tionality. In our previous work, we investigated the behavior of renal
and liver cells cultivated inside such PDMS microﬂuidic biochips. More
particularly, we compared the transcriptomic and proteomic proﬁles
of MDCK cells and HepG2/C3a cultivated in dynamic conditions in a
micro environment and in Petri [5,6]. The transcriptomic and proteomicrights reserved.integration in the renal biochip showed that various transporters in-
volved in typical kidney functions (such as calcium, phosphate, sodium,
H+ protons homeostasis) were up-regulated during microﬂuidic cul-
tures. In addition, for both hepatic and renal tissues, we found that the
Nrf-2 dependent pathways and early inﬂammation, which results in a
global cytoprotective response, were induced during the microﬂuidic
cell cultures. This led to observations of the induction of genes related
to cellular defense mechanisms such as the up-regulation of phase I
and II enzyme drug metabolism, various multidrug resistance genes
(MRP) and phase III transporters (SLC) (which appeared convenient for
hepatic metabolism applications) [7]. However, the cells never reached
an apoptotic situation as long as the levels of enzymes such caspases 3
remained similar in the biochip and Petri cultures [5,6]. Therefore, the
biochip cultures appeared to provide a cellular model for exploring the
early stages of cell inﬂammation and the related mechanistic response.
In parallel, the possible molecular interaction between inﬂamma-
tion and cancer pathways are being investigated more and more, but
still remain unclear [8]. The role of pro-inﬂammatory cytokine tumor
necrosis factor (TNF)-α, or the role of nuclear factor-κB (NFKB) tran-
scription factors were postulated as being a potential key factor in
inﬂammation-ﬁbrosis-cancer [8,9]. Furthermore, IKK/NFKB signaling
was proposed as a potential bridge connecting inﬂammation and cancer
[8]. To explore the beneﬁts of an inﬂammation model using the micro-
ﬂuidic biochip in the context of cancer therapy research, we compared
MDCK cell response in biochips and Petris when treated with an anti-
neoplastic compound. We chose to work with ifosfamide. To be used
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into the cytoactive ifosfamide-mustard. It acts as a DNA alkylating
agent leading to its mode of cytotoxic effect on tumors by causing
both inter- and intra-strand crosslinks [10]. In addition, ifosfamide's
tubular metabolism and liver metabolism lead to the formation of
chloroacetaldehyde and acroleine, which are both active and nephro-
toxic metabolites [11,12]. In the present investigation, so as to avoid
interaction between the ifosfamide itself and its active acrolein and
chloroacetaldehyde metabolites, we used kidney MDCK cells that can-
not metabolize the ifosfamide up to these nephrotoxic compounds.
Theﬁnal purpose of the studywas to investigate directly the compound's
effect on the kidney inﬂammation induced by the biochips. For compar-
ative purposes, we investigated the MDCK response in microﬂuidic bio-
chips and in Petri cultures (plate conditions). Finally, we chose a dose
of 50 μM of ifosfamide because it is a plasmatic concentration found in
therapeutic conditions [13].Cell seeding Cell counting
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2.1. 50 μM of ifosfamide did not affect MDCK cell cultures in Petri
conditions
We did not detect any effect of the ifosfamide treatment at 50 μM in
Petri cultures. In both treated and control cases, cell morphology and vi-
ability were similar (Fig. 1). Cell proliferation was not affected by the
treatment as the number of cells was multiplied by 3 in both situations
(Fig. 2A). Cell cycle distribution was not affected by the treatment
either, leading us to observe similar G1, S and G2/M distribution in
both the treated and control conditions (Fig. 2B). In addition, the statis-
tical treatment applied to the microarray data revealed that it was not
possible to separate the treated and control conditions in Petri cultures
(Fig. 3). Thus, statistically, we identiﬁed only 12 genes affected by the
treatment in the transcriptomic analysis. The metabolic analysis thenure media
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consumption. In the control and treated cases, glucose consumption
was 11±1 and 15±2 μg/h/106cells respectively. For glutamine, we
found values equal to 36±13 and 42±6 μmol/h/106cells respectively.
Finally, we did not detect any ifosfamidemetabolites in the culture me-
dium from the mass spectrometry analysis.
2.2. Transcriptomic analysis revealed cytoprotective and inﬂammatory
responses induced by the microﬂuidic biochips to the MDCK cell cultures
At ﬁrst, theMDCK cells successfully attached to the biochips (Fig. 1).
The behavior of the MDCK cells in the biochips was modiﬁed when
compared to Petri cultures. This result has already been reported in
our previous work [6]. A delay in proliferation occurred during the cul-
tures due to adaptation to the micro environment. This was illustrated
after the ﬁrst 24 h of culture before the ﬂow was started. At that time,
we found a higher G1 phase and lower S phase in the cell cycle of
theMDCK in the biochipswhen compared to the Petri (Fig. 2C). In addi-
tion, in the microarray analysis, this delay was associated with a cyto-
protective cellular response leading to various anti-inﬂammatory
signaling pathways in the biochips. In the comparison, 666 genes with
a fold change ofmore than 2 (or less than−2)were expressed differen-
tially according to the comparisons (Table 1). The Ingenuity Pathway
Analysis (IPA) was conducted on the gene lists to identify the main
functions affected in the biochips when compared to the Petri ones.
The biochip effect was illustrated in the “top tox list” by “Oxidative
stress” and the “Nrf-2 pathway”. In addition, the integrin signaling path-
ways were up-regulated. This result illustrated a difference in the adhe-
sion phenomena in the biochip.
The MDCK cells then proliferated when the ﬂow perfusion was
started (Figs. 1, 2). The transcriptomic time lapse analysis showed that
this inﬂammatory response was still observed after 96 h of culture. In
this second comparison, 6055 genes with a fold change of more than
2 (or less than−2)were expressed differentially according to the com-
parisons (Table 1). After 96 h of culture in the biochip, we found that
“Oxidative phosphorylation”, “Mitochondrial dysfunction” and “Nrf-2
mediated stress oxidative response” pathwayswere among the top net-
works signiﬁcantly modulated by the microﬂuidic culture (Table 1).
In addition, these pathways may be related to cancer. Thus, in the top
bio functions the IPA analysis revealed 861 genes involved in the dis-
eases and disorders of cancer. The most functional genes shown in
Table 2 were involved in cell cycle andDNA damage and repair, cell sig-
nalling, adhesion and apoptosis. However, our previous works demon-
strated that the cells did not reach apoptotic levels [6].) Biochip cultures 
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Table 1
Relevant pathway extracted by the Ingenuity analysis based on the micro array data. * denotes data already presented in Snouber et al., 2011.
Comparison Pathway P-value
Biochip control vs petri control after 24 h of cultures (666 genes)* Caveolar-mediated endocytosis signaling 1.14×10−5
NRF2-mediated oxidative stress resp 1.17×10−5
Fatty acid elongation in mitochondria 1.03×10−4
Integrin signaling 1.86×10−4
Biochip control vs petri control after 96 h of cultures (6055 genes)* Mitochondrial dysfunction 3.35×10−13
Oxidative stress resp. mediated by Nrf2 2.78×10−7
G2/M transition of the cell cycle 1.25×10−5
Cholesterol biosynthesis 1.51×10−5
Oxidative stress 3.26×10−5
Petri control vs petri treated after 96 h of cultures including 72 h of ifosfamide treatment (12 genes) Xenobiotic metabolism 1.25×10−2
Oxidative stress 1.30×10−2
Aryl hydrocarbon receptor signaling 2.99×10−2
Biochip control vs biochip treated after 96 h of cultures including 72 h of ifosfamide treatment (336 genes) Integrin signaling 3.48×10−5
ATM signaling 5.06×10−5
NRF2 mediated oxidative stress response 1.13×10−4
Cell cycle, DNA damage, checkpoint regulation 1.45×10−4
G2/M transition of the cell cycle 8.51×10−5
Anti-apoptosis 7.61×10−4
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cancer response in MDCK cell cultures in biochip conditions treated with
50 μM of Ifosfamide
In both treated and control perfusion conditions, cell morphology,
proliferation and cell distribution in the cell cycle were not affected by
the treatment in the biochips (Figs. 1, 2A and C). Glucose and glutamine
consumptionwas not affected by the treatments.Wemeasured glucose
consumption of 44±2 and 40±5 μg/h/106cells in the control and
treated biochips respectively. For glutamine, we reached values equal
to 158±7 and 168±17 μmol/h/106cells respectively. The search for
ifosfamide metabolites using mass spectrometry demonstrated that the
compound was not biotransformed by the MDCK cells in the biochips.
These results are similar to, and consistent with, those obtained in the
Petri.
The transcriptomic analysis performed by microarray revealed a
difference at the gene level between the treated and control condi-
tions in the biochip cultures. Statistical data processing successfully
separated the culture conditions in the biochips. In the comparison,
we extracted 336 genes with a fold change of more than 1.5 (or less
than −1.5) that were expressed differentially (Table 1). Of the 336
genes listed, the Ingenuity Pathway Analysis (IPA) identiﬁed 94 genes
reported in cancer studies. In Table 2 we present a selective list of 16Table 2
Fold change of functional genes involved in cancer expressed in biochip when com-
pared to Petri before ifosfamide exposure.
Oncogenes Biochip control
vs petri control
after 24 h of
cultures
Biochip control
vs petri control
after 96 h of
cultures
Cell cycle & DNA
damge repaire
ATM – –
CDKN1A – 2806
TP53 – –
MDM2 2234 4350
Apoptosis BAX – 2374
BCL2A1 – 4059
CASP8 2652 2815
HTATIP2 – 4432
Signal Transduction Molecules
and Transcription Factors
FOS – 2364
MAP2K1
(MEK)
– 161
MYC – 4195
NFKB1 – 170
NFKBIA – 9397
Adhesion ITGB1 2850 2589
ITGB3 2418 2588
ITGAV – 3702genes. The Ingenuity Pathway Analysis applied to this comparison in
the biochip also demonstrated that the “integrin signaling,” “ATM sig-
naling,” “Nrf-2 mediated stress oxidative response,” “G2/M Transition
of the Cell Cycle,” “Cell cycle, DNA damage checkpoint signaling” and
“anti-apoptosis” pathways were modulated by the ifosfamide treat-
ment in themicroﬂuidic cultures (Table 1). The genes affectedmost sig-
niﬁcantly in the pathways are shown in Table 3. Thus, in ATM signaling
andG2/M cell cycle transition, we found up-regulation of cyclins B1 and
B2 (CCNB1 and CCNB2) and CDK1 genes. In the anti-apoptotic signaling,
we found that BCL2A1, BAG3 and MCL1 were down-regulated in the
treated biochips when compared to the control ones. In addition,
regarding the Nrf-2 pathway, the heat shock protein genes of two
HSP40 (DNAJB4 and DNAJB9), HSP70 and HSP 22 kDa (HDPB8) were
down-regulated. The Nrf-2 pathway was also affected, with down-
regulation of the TXNRD1 gene (coding for a protein involved in the
response to oxidative stress). Then, regarding inﬂammatory response,
NFKBIA (IkBα), the TNFAIP3 genes involved in the NFKB signaling path-
way and the heat shock proteins HSP 60 (HSPD1) and HSP 105 (HSPH1)
were found to have been down-regulated. In addition, the MYC proto-
oncogene involved in numerous pathways related to cell proliferation
and tumor genesis was found to have been down-regulated (value
equal to−1.5). Finally, several drug and ion transportersweremodulat-
ed by the ifosfamide.
To complete the interpretation of the microarray results, we added to
our investigation an RTqPCR analysis (Table 4). At ﬁrst, the inﬂammatory
response (without ifosfamide treatment) induced by the biochip cultures
when compared to Petri was conﬁrmed by the up-regulation of the TP53
and CIP1 genes coding for proteins 53 and 21 respectively. Both genes are
involved in mediation of cell cycle arrest and apoptosis signaling path-
ways (via the p53 signaling and ATM pathway). In addition, the high
levels of glutathione S transferase 3 (GSTA3, involved in protecting
against oxidative stress) in the biochip cultures when compared to Petri
illustrated the induction of the cytoprotective MDCK response. Interest-
ingly, in the ifosfamide-treated conditions, an anti-inﬂammatory re-
sponse related to the treatment was conﬁrmed by the down-regulation
of the TP53 and CIP1 genes when compared to biochip controls. On the
contrary, no effect on these genes was detected in the Petri. In addition,
the levels of GSTA3 were down-regulated in the treated biochips, illus-
trating the reduction in the cytoprotective mechanism.
3. Discussion
Introducing genes to identify the over-represented metabolic path-
ways was performed by mapping the metabolic signature using the
KEGG database [14] and Ingenuity canonical pathways (Ingenuity®
Systems). The transcriptomic analysis, resulting from microarray and
Table 4
Comparison of the level of mRNA analyzed by RTqPCR. Data are expressed in
percentage.
Gene name Biochip control
versus petri
control
Biochip control
versus biochip
treated
Petri control
versus petri
treated
Petri Biochip Control Treated Control Treated
CDKN1/CIP1 (p21) 100 241 100 57 100 114
GSTA3 100 4244 100 61 100 117
TP53 (p53) 100 147 100 84 100 102
Table 3
Relevant genes affected by the ifosfamide treatment in biochips and extracted from the
highlighted canonical pathways by Ingenuity analysis. Genes with fold change above
1.5 (and below −1.5) are presented (* denotes genes also presented in Table 2).
Anti apoptotic related genes
Gene ID Gene name Fold
change
BAG3 BCL2-associated athanogene 3 −1518
BCL2A1* BCL2-related protein A1 −2770
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) −1812
ATM signaling and G2/M transition of the cell cycle related genes
CCNB1 cyclin B1 1.819
CCNB2 cyclin B2 1.835
CDC2/
CDK1
cyclin-dependent kinase 1 1.537
CDKN2C cyclin-dependent kinase inhibitor 2 C
(p18, inhibits CDK4)
1.598
GADD45B growth arrest and DNA-damage-inducible, beta −1.998
NFKBIA* nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha
−2354
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 1.538
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 −1.503
WEE1 WEE1 homolog (S. pombe) −2.058
YWHAE tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, epsilon
polypeptide
−1.748
Nrf-2 mediated and oxidative stress response related genes
ACTB actin, beta −2083
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 −1.565
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 −1.702
FKBP5 FK506 binding protein 5 −2.528
HERPUD1 homocysteine-inducible, endoplasmic reticulum −1.812
HDPB8 heat shock 22 kDa protein 8 −1.696
HSPA9 Heat shock 70 kDa protein (mortalin) −1.803
HSPD1 heat shock 60 kDa protein 1 (chaperonin) −1.68
HSPH1 heat shock 105 kDa/110 kDa protein 1 −1.535
MAPK1 mitogen-activated protein kinase 1 −1.563
RRAS2 related RAS viral (r-ras) oncogene homolog 2 −1.741
TXNRD1 thioredoxin reductase 1 −1.956
Integrin signaling related genes
ACTB actin, beta −2083
ARF5 ADP-ribosylation factor 5 1.511
MYC* −1.5
ITGA5 integrin, alpha 5 −1.945
ITGA6 integrin, alpha 6 −1.712
ITGA7 integrin, alpha 7 1.625
ITGB6 integrin, beta 6 −1.721
MAPK1 mitogen-activated protein kinase 1 −1.563
PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme −1.736
RND3 Rho family GTPase 3 −1.88
RRAS2 related RAS viral (r-ras) oncogene homolog 2 −1.74
WASL Wiskott-Aldrich syndrome-like −1.516
Transporters related genes
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP),
member 5
−2.112
ATP11B ATPase, class VI, type 11B −1.535
ATP6V1H ATPase, H+transporting, lysosomal 50/57 kDa,
V1 subunit H
−1.681
ATP8B1 ATPase, class I, type 8B, member 1 −1.591
SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion
transporters), member 2
−1.784
SLC23A2 solute carrier family 23 (nucleobase transporters),
member 2
−1.607
SLC25A30 solute carrier family 25, member 30 −1.538
SLC25A33 solute carrier family 25, member 33 −1.659
SLC38A1 solute carrier family 38, member 1 −1.536
SLC7A1 solute carrier family 7, (cationic amino acid transporter,
y+system) member 11
−2.508
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model. The ﬁrst effect was illustrated by amodulation of the gene relat-
ed to the inﬂammatory response of the MDCK cells when they werecultivated in ifosfamide-treated biochips in comparison to the control
biochips. The second effect can be related to modulation of the cancer/
apoptotic/anti-apoptotic pathways.
Mapping the 336 genes extracted from the microarray and RTqPCR
analyses, we found that ifosfamide modulated the MAP kinase sig-
naling pathway by down-regulating the GADD45, PPM1A, FLNB,
RRAS2,MAPK1 andMYCgenes that are involved in proliferation and ap-
optosis controls (Sup. Fig. 1). In addition, p53 modulation was illustrat-
ed by lower expression in the TP53 and CIP1 genes. p53 is involved in
the ATM signaling pathway via regulation control of the cyclin B1, B2
and CDK1 genes (Sup. Fig. 2). These signaling pathways were reported
in the genotoxic stress response and in gene therapy in tumor treatment
[15]. In addition, ifosfamide played a part in down-regulating the anti-
apoptotic pathways via down-regulation of the BCL2A1, BAG3 and
MCL1 genes. Therefore, this part of the data setmay suggest a cellular re-
sponse due to ifosfamide leading to a reduction in the cellular defence
mechanism in the MDCK cultivated in the biochips.
In addition, among the genes targeted by ifosfamide in the micro-
ﬂuidic biochips, we found that the treatment led to the down-
regulation of the TXNRD1 gene in the Nrf-2 pathway. This ﬁnding is
consistent with in vivo results in which ifosfamide has been reported
to inhibit thioredoxin reductase activity in mice with hepatoma cells
(H22 cells, [16]). The TXNRD1 gene codes for thioredoxin reductase,
which is reported to be involved in the response to oxidative stress.
In addition, thioredoxin is also reported to inhibit apoptosis, stimu-
late cell proliferation and increase transcription factor activity [17].
Thioredoxin reductase has therefore been proposed as a potential
molecular target for anticancer agents as it is over expressed in
many tumor cells and exhibits pro-survival signalling [16,18]. De-
spite the fact that the ifosfamide inhibition mechanism is not clearly
deﬁned, our results may suggest down-regulation via the down-
regulation of MAPK1 and RRAS2 in the Nrf-2 pathway.
Furthermore, we also found that the HSP40, HDPB8, HERPUD1 and
FKBP5 geneswere all targets affected (down-regulated) by the ifosfamide
treatment in the Nrf-2 pathway. In total we found ﬁve HSP genes down-
regulated, including Hsp40, HSP60 and HSP 70. HSP40, 60 and 70 are
chaperones (or co-chaperones) induced after certain types of cell stress
such as oxidative damage [19]. In addition, in general, chaperone up-
regulation is involved in tumorigenesis [19]. Thus, in the context of can-
cer therapy, chaperone heat shock proteins (HSP) have been identiﬁed
as potential candidates for drug targets [20]. They are effectively reported
to be involved in signal transduction pathways leading to proliferation,
cell cycle progression and apoptosis [19,20]. More particularly, HSP40 is
essential for chaperone activity and its interaction with the HSP70 chap-
erone; both are involved in various cell proliferation and apoptosis path-
ways [21–23].
We then found a signiﬁcantly reduced number of 94 functional genes
involved in cancer. Of them, the MDM2 gene, which regulates p53,
which in turn negatively controls its activity and stability [24–26], is
overexpressed with a high fold change (4.35) in the biochip compared
to Petri dishes after 96 h of culture. But this gene appeared completely
unexpressed in the presence of ifosfamide in the biochip cultures. This
may mean maintaining p53 activation (in biochips compared to Petri)
to ensure its action as a transcription factor to activate expression of
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DNA repair, cell cycle progression and apoptosis (in addition, p21 will
allow Nrf-2 activation of the antioxidant response [27]). Furthermore,
our data suggested that biochips and ifosfamide may affect RAS activa-
tion in MDCK cells. RAS controls activation of the MAP Kinase pathway
which phosphorylates and activates p53. It induces the expression of
ARF, which in turn binds to and inhibits MDM2, leading to a display of
a typical response observed in anticancer therapy [28]. However, future
tests will be required to conﬁrm this hypothesis.
On the other hand, we found a modiﬁcation in integrin signaling
(Sup Fig. 3). It is known that integrins mediate organization of the
actin cytoskeletonwhich is essential for proper localization and translo-
cation of activated ERK1/2 and in turn, the ability of ERK1/2 to efﬁciently
phosphorylate nuclear substrates [29,30]. In addition, activation of the
ERK1/2 pathway has been documented in leukemia, renal cell carcino-
ma, breast cancer, and in several ovarian cancer cell lines [31–35]. Fur-
thermore, the β1 integrin signaling pathway is reported as promoting
expression of MYC protein [36]. In this context, we found down-
regulation of the MYC proto-oncogene that encodes a ubiquitous tran-
scription factor involved in cell proliferation and tumorigenesis [37].
Thus, MYC is very often found to be up-regulated in many types of
cancers.MYC is activated by variousmitogenic signals and, interestingly,
in our study it appeared that MYC was down-regulated via the RRAS2
and MAPK1 pathway. MYC has already been reported as being capable
of driving cell proliferation (up-regulates cyclins, down-regulates
p21). It has also been found to play role in regulating apoptosis (down-
regulates Bcl-2), and involved in p53 signaling [37,38]. MYC is involved
in direct regulation of heat shock proteins such as HSP60 [38]. This set
of literature reports appeared consistent with the results found in our
transcriptomic analysis in which similar correlations were observed.
However, future investigations will be needed to be able to clarify the
bridges between ifosfamide treatment, the biochip culture response via
this integrin pathway and the global anti-inﬂammatory response.
Literature works including ifosfamide microarray have shown that
poor ifosfamide responders in osteocarcinoma xenografts were related
to negative regulation of the “physiologic process”, “apoptosis”, “calcium
ion binding” and “microtubule cytoskeleton” gene oncology enrichment
[39]. Futhermore, silencing IER3 and S100A2 genes in osteocarcinoma
cells has shown to reduce colony formation after ifosfamide treatments
[39]. Biochip cultures contributed to down-regulating S100A2 but up-
regulated IER3 (fold change at−6.48 and 4.8 respectively) when com-
pared to Petri situations in untreated conditions. Finally, the biochips
also modulated pathways related to cytoskeleton (via the integrin path-
way) and apoptosis signalling. Finally the toxicity of ifosfamide has
recently been reported via the activation of the OCT2 gene (organic cat-
ion transport 2) in proximal tubule cells [40]. Although we did not ﬁnd
such gene modulation in our model, the biochip cultures played a part
in affecting up to 38 solute carrier transporter genes when compared to
Petri cultures without ifosfamide [6]. Furthermore, the ifosfamide treat-
ment in the biochips appeared to modulate the genes involved in solute
transporters (including cations via ATP11B). This may suggest other
transporters could be involved in ifosfamide sensitivity.
4. Conclusions
In summary,we investigated the effects at the transcriptomic level of
ifosfamide onMDCK cells cultivated inmicroﬂuidic biochips. Themicro-
ﬂuidic biochip cultures induced an early inﬂammatory response in the
MDCK cells. The ifosfamide treatment in the Petri had no effect on the
MDCK cells. On the contrary, in biochips, the treatment induced a reduc-
tion in inﬂammatory responses via modulation of the Nrf-2, ATM, p53
and NFKB pathways. Reduced inﬂammation was also correlated with
a perturbation in the integrin pathway. The c-MYC proto-oncogene
appeared to be a pivotal candidate involved between integrin pathway
perturbation and the anti-inﬂammatory response. Several cancer thera-
peutic targets were also modulated by ifosfamide in the biochips oncontrary to Petri conditions. Interestingly, we believe that the micro-
ﬂuidic biochip cultures may be potential models for studying tissue
inﬂammation and the bridges between cancer and inﬂammation. Our
results may open up new analysis strategies using alternative in vitro
methods in predictive toxicology and oncology.
5. Material and methods
5.1. Biochip production
The production details, based on replica moulding of pol-
ydimethylsiloxane (PDMS), and the biochip design have been speciﬁed
previously [41,42]. In summary, the biochip is built with a ﬁrst PDMS
layer with microstructures for cell attachment, containing a series of
microchambers andmicrochannels inside a larger cell culture chamber.
The biochip has an estimated volume of 40 μL. The total surface avail-
able for cell growth is about 2 cm2 including the microchannel walls.
5.2. Cell culture conditions
Madin-Darby canine kidney cells (MDCK) were purchased from the
American Type Culture Collection (ATCC-CCL-34). The cells were cul-
tured in Minimum Essential Medium (MEM, eagle) with 10% fetal bo-
vine serum, 2 mmol/L L-Glutamine, 0.1 mmol/L non-essential amino
acids, 1 mmol/L sodium pyruvate, 10 mmol/L HEPES buffer and 100
units/mL of penicillin and streptomycin (Gibco).
The protocol is presented in Fig. 1. Cell adhesion was enhanced by
a surface treatment with 10 μg/mL of ﬁbronectin solution (Roche) for
40 min in the biochips and in the 12-well Petri dishes. The Petri dis-
hes were initially covered with 0.5 mL of PDMS and used as controls
for the PDMS biochips. The cells were seeded at a density of 0.2×106
cells/cm2. Cell adhesion took place over 24 h. After that, the biochips
and Petri dishes were rinsed with culture medium in order to remove
any unattached cells. The culture mediumwas changed in the Petri dis-
hes. The biochips were connected to a perfusion loop including the cul-
turemedium tank and the peristaltic pump. The biochipswere perfused
at a ﬂow rate of 10 μL/min for 72 h; this resulted in 96 h of culture. Fig. 1
shows the experimental procedure. All cell culture steps were per-
formed at 37 °C inside a 5% CO2 incubator.
5.3. Cell cycle analysis
Cells were washed with 500 μL of phosphate-buffer saline (PBS)
and were trypsinized inside the biochip by perfusing 500 μl of a solu-
tion containing 25 mg/mL of trypsin and 100 μg/mL of EDTA (Gibco).
The cells collected were washed twice with PBS containing 5 mmol of
EDTA (centrifugation at 5000 rpm for 5 min at 4 °C). They were ﬁxed
for 45 min with 1 mL of ice-cold ethanol 75% in PBS. After washing in
PBS, the cells were suspended with PBS containing 5 mmol of EDTA,
0.1% Triton X-100, 40 μg of RNase A and 25 μg of propidium iodide.
The cells were incubated for 15 min protected from light. The stained
samples were analyzed in an Epics XL-MCL ﬂow Cytometer (Beckman
Coulter). The histograms were analyzed using Multicycle AV software.
5.4. Cell counting, viability and metabolism activities
Cells were counted by cell detachment with trypsin-EDTA and cou-
nting on aMalassez cell. Viabilitywas quantiﬁed by trypan blue staining.
Metabolism activities such as glucose consumption and ammonia
production were carried out with the Konelab 20 biochemical analyzer
(ThermoElectron Corporation). The protocols have been described in de-
tail in our previous works [15,42]. Brieﬂy, glucose was measured using
the glucose oxidase method and a modiﬁed Trinder color reaction cata-
lyzed by the enzyme peroxidase GOD-POD Kit (Thermo Electron Corpo-
ration). Ammonia production was measured using the enzymatic UV
method (Randox), in which the reaction consists in combining ammonia
33L. Choucha Snouber et al. / Genomics 100 (2012) 27–34with α-ketoglutarate and NADPH in the presence of glutamate des-
hydrogenase to yield glutamate and NADP+. The corresponding de-
crease in absorbance at 340 nm is proportional to themedium's ammonia
concentration.
Glutamine consumptionwasmonitoredusing aGlutamine/Glutamate
determination Kit (GLN-1 Sigma). Determining L-glutamine is a two-step
reaction: deamination of L-glutamine to L-glutamate and dehydrogena-
tion of the L-glutamate to α-ketoglutarate accompanied by reduction
of the NAD+ to NADH. The conversion of NAD+/NADH is measured
by spectrophotometer (Hitachi U-2001 Spectrophotometer) and is pro-
portional to the amount of glutamate that is oxidized, hence the amount
of glutamine converted to glutamate in the samples.
5.5. RNA isolation, hybridization and microarray analysis
For the microarray study, the cells were trypsinized from themicro-
ﬂuidic biochip and well plates. Total RNA was extracted using the
Nucleospin® RNA XS isolation kit (Macherey-Nagel). The quantity of
RNA was assessed with a Nanodrop ND-1000 spectrophotometer
(Nyxor Biotech, Paris, France). The quality of the RNAextractedwaseval-
uated using the Agilent 2100 Bioanalyzer (using the Agilent RNA6000
nano chip kit). All RNA samples had an RNA Integrity Number (RIN) of
more than 8 (between 9.3 and 10).
Ten Affymetrix GeneChip Canine Genome 2.0 Arrays (Affymetrix®)
were used for RNA microarray analysis. Each one included a mixture
of duplicate samples from two biochips or two plate wells, and the
Affymetrix® protocols were followed to process these microarray
chips. For these steps, 1 μg of total RNA was reverse transcripted, and
the resulting double strand cDNA was used for in vitro transcription
with T7 RNA pol (using the Affymetrix WT cDNA Synthesis and Am-
pliﬁcation Kit). After fragmentation, the cDNA was end labeled with
biotin using terminal transferase (using the Affymetrix® WT termi-
nal labeling kit). The cDNA was then hybridized to GeneChip canine
2.0 arrays. After overnight hybridization, the chips were washed on
the ﬂuidic station FS450 following speciﬁc protocols (Affymetrix)
and scanned using the GCS3000 7 G.
The resulting images were analyzed using Expression Command
Consol software (Affymetrix®) to generate .cel ﬁles, which contain
the raw intensity values of each probe. RMA (Robust Multichip Aver-
age) normalization methods were used to convert the probe level in-
tensity data into normalized probe-set level intensity data. Using R, a
non-standardized hierarchical clustering method was applied to nor-
malized data making it possible to separate the 2 biological groups
and store the triplicates together. A Welsh T-test was used to identify
genes expressed differentially (using Mev software). The gene lists se-
lected by the T-test (p value of less than 0.05) were ﬁltered according
to the fold change in order to conserve only the geneswith a fold change
of more than 2 (up-regulated) or less than −2 (down-regulated). To
examine the gene networks, including biological processes, cellular
components, molecular functions, and genetic networks, the data
were analyzed using Ingenuity Pathway Analysis (IPA) tools (Ingenuity
Systems). Differentially expressed genes thatwere associatedwith a ca-
nonical pathway in the Ingenuity Pathway Knowledge Base were con-
sidered for evaluation.
5.6. RTqPCR analysis
Quantitative RT-PCR was performed using the Sybr green Master
Mix (Roche) and the real time PCR system LC480 (Roche). Brieﬂy,
total RNA samples were all controlled for quality using the Bioanalyzer
2100 and RNA6000 nano chip kit. cDNAwas synthesized from500 ng of
total RNA with oligodT priming using superscript II (Life technologies)
following the manufacturer's recommendations. Pairs of primers for
each of the target genes (CDKN1A1 (p21); TP53 (p53), GSTA3 (beta
actine)) were designed with the NCBI PrimerBlast tool (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/) on the Canis lupus familiaris 2.2build, and tested for efﬁciency and speciﬁcity. Validated pairs were
used in triplicate. Data from target genes were normalized with
two reference genes (UBC and HPRT) obtained from a pilot study
on certain housekeeping genes with the Genorm algorithm, allowing
us to select these twomore stable reference genes in our model. Data
were analyzed using the ΔCt method after validation of each tripli-
cate (i.e. elimination of extreme measures from the triplicates with
standard deviation above 0.3).
5.7. Mass spectrometry analysis
In order to identify whether the effect of ifosfamide on the MDCK
cells was because of the compound itself and/or its metabolites, we per-
formed a mass spectrometry search for the metabolites in the culture
medium. As acrolein and chloroacetaldehyde could not be detected by
mass spectrometry (problem with ionization) we searched their inter-
mediate metabolites: 4-keto-ifosfamide, 2-dechloroethyl-ifosfamide,
and 3-dechloroethyl-ifosfamide. We also searched for isophosforamide
mustard.
The samples of culture medium were stored at−80 °C. 50 μL of the
samples were mixed with 150 μL of methanol to precipitate the protein.
Thenwedid an 18,000 g centrifugation (for 10 min at 4 °C). Supernatants
were evaporated (nitrogen ﬂux, turbovap) and then diluted in water/
methanol (50/50). 1/3 of the solution was diluted in deionized water
for the LC/MS analysis. The analysis was performed using liquid chroma-
tography (Agilent 1100 series) and amass spectrometer (Exactive, Ther-
mo Fisher Scientiﬁc) using electrospray ionization. The chromatographic
column used was an Agilent Zorbax SB-C18. The chromatographic sepa-
ration was performed using a gradient optimized for 10 min analysis
(A solution:water/acetonitrile 95/5+0.1% formic acid; B solution: aceto-
nitrile+0.1%formic acid). The MS detection was performed in positive
ionization over the m/z 50 to 500 range, with a spectral resolution of
50 000 (FWHM=full width at half maximum). Total run time was
30 min. The injection volume was 20 μl for each sample and retention
time for the ifosfamide, 4-keto-ifosfamide, isophosphoramide mustard,
ifosfamide, 2-dechloroethyl-ifosfamide, and 3-dechloroethyl-ifosfamide
were 6.12, 5.96, 1.4, 16.2, 1.9 and 3.08 min respectively.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2012.05.001.
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